NCT05812807 2026-03-04
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
Alliance for Clinical Trials in Oncology
Rutgers, The State University of New Jersey
University of Pittsburgh
IFOM ETS - The AIRC Institute of Molecular Oncology
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Cliniques universitaires Saint-Luc- Université Catholique de Louvain